Reference
A dose is not an abstract fact with a single owner. Regulators approve one schedule, clinical trials study another, clinics observe a third, and online forums discuss a fourth. Therapept separates these tiers completely instead of averaging them.
Official Label
FDA-approved PI
Human Trials
Registered protocols
Clinical Ref
Physician observation
Animal Study
Preclinical models
Community
Unverified reports
Every numerical record on Therapept belongs strictly to one of five source categories. They are never averaged together, and community discussions are never used to validate an unapproved dose.
Approved indication, route, dose, frequency and titration, sourced only from the FDA label, DailyMed or the manufacturer's prescribing information.
Intervention parameters reported in individual published human studies. Each study stays separate; parameters are never aggregated across studies.
Clearly labelled animal research. Animal dosing is never visually mixed with human study data and is not evidence of human response.
Protocols published by identifiable professional, clinic or pharmacy sources, recorded with author/clinic, date accessed and context.
What people report discussing or doing in forums, on Reddit and in videos. Included only to show demand and reported practice — never as clinical evidence.
Showing 12 of 12 indexed dosing records
View Full Comparison Grid →GLP-1 receptor agonist (acylated GLP-1 analogue)
An approved drug with a labelled dose schedule. The label is the authoritative source; research-chemical copies of liraglutide are not the labelled product.
Growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist. Synthetic pentapeptide containing unnatural amino acids
No approved product exists. Human data are limited to pharmacology studies of the compound itself; everything beyond those studies comes from lower source tiers.
Growth hormone-releasing hormone (GHRH) analogue. Supplied in two chemically distinct forms
Two distinct molecules share this name. The published human trials used the DAC (albumin-binding) form; the non-DAC fragment sold as “Mod GRF 1-29” has no comparable published human dose data in this file.
Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC
No approved product and no registered human trials in this file. The only human data indexed are a small retrospective case series; animal literature is extensive but comes from largely one research network.
Synthetic acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 (residues 17–23)
The published human dose picture for the TB-500 fragment specifically is effectively empty: the wound-healing literature concerns full-length thymosin β4, a different molecule. Compound-specific confusion is the story here.
Cyclic heptapeptide; non-selective melanocortin receptor agonist (alpha-MSH analogue)
A pilot Phase I study exists; no approved product. The study's own conclusion was about dose selection for future Phase I work, not therapy.
GLP-1 receptor agonist (acylated GLP-1 analogue)
An approved drug with labelled schedules. Unapproved GLP-1 products are a separate regulatory matter and their contents are not the labelled drug.
Investigational triple agonist of GIP, GLP-1 and glucagon receptors
An investigational triple agonist (GIP, GLP-1, and glucagon receptors) in Phase 3 clinical development. There is no FDA-approved formulation, no approved prescribing label exists, and research chemicals sold online are unverified for purity or sterility.
Dual GIP and GLP-1 receptor agonist
An approved dual GIP/GLP-1 receptor agonist with authoritative prescribing labels. Compounded or research-grade copies are chemically distinct and lack FDA safety verification.
Stabilised GHRH analogue — human GHRH(1-44) amide, N-terminally acylated
An FDA-approved growth hormone-releasing factor analogue specifically indicated for HIV-associated lipodystrophy. Other cosmetic, bodybuilding, or anti-aging uses discussed online are unapproved.
GHRH analogue — human GHRH (1-29) amide
A 29-amino acid GHRH fragment (GHRH 1-29 amide). Formerly FDA-approved as Geref for diagnostic pituitary evaluation and idiopathic growth hormone deficiency.
Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. Cosmetic ingredient under the INCI name Copper Tripeptide-1
A naturally occurring copper tripeptide (glycyl-L-histidyl-L-lysine:copper). Primarily studied in topical dermatological formulations and animal tissue regeneration models.
Coverage Note:
Looking for a compound not listed here? If a substance is absent from this hub, it means Therapept has not yet indexed verified clinical trial or official label records for it — not that no discussion exists. Consult the Peptide Library (42 compounds) for chemical identities and regulatory classifications.
Dosing references last reviewed 22 September 2026 · Therapept Editorial · How these records are built
